K

S

Section 32

Crunchbase
Pitchbook
Crunchbase

Deals on record

8

Common Fundraising Type

Series B

C
Character Biosciences

Precision medicine • Drug development

Character Biosciences is a precision medicine company focused on developing therapies for degenerative eye diseases, particularly age-related macular degeneration.

Series B
$93M
03/25/2025
Article
S
Sola

Insurtech • Natural disaster insurance

S Capital logo
S32 logo
Glilot Capital Partners logo

Sola is an insurtech company that provides natural disaster insurance using advanced weather data and automated claims processing for fast payouts.

Seed
$30M
03/11/2025
Article
S
Sola Security

Cybersecurity • No-code

S Capital logo
S32 logo
Glilot Capital Partners logo

Sola Security provides a self-serve cybersecurity platform that enables businesses to build and deploy custom security applications without extensive technical expertise using a no-code studio and AI-powered builder.

Seed
$30M
03/11/2025
Article
S
SandboxAQ

Quantum computing • Software development

T. Rowe Price Associates logo
US Innovative Technology Fund logo
S32 logo
Rizvi Traverse logo

SandboxAQ develops quantum physics-based software for applications in life sciences, materials science, navigation, encryption, and cybersecurity.

Equity
$300M
12/18/2024
Article
T
TollBit

Real-time payments • AI companies

Lightspeed logo
Section 32 logo

TollBit provides a platform for real-time payments between AI companies and publishers to help content creators monetize their data usage effectively.

Series A
$24M
10/22/2024
Article
S
Sunbird Bio

Biotechnology • Blood-based diagnostics

Polaris Partners logo
S32 logo
Eli Lilly and Company logo
EDBI logo

Sunbird Bio develops a blood-based diagnostic platform for early and accurate detection of neurological disorders like Alzheimer’s and Parkinson’s disease.

Equity
$14M
10/16/2024
Article
B
Basecamp Research

AI platform • Biological insights

S32 logo
Singular logo
redalpine logo

Basecamp Research is a London-based startup developing an AI platform for biological insights by building a comprehensive database of primary-source biological data for applications in drug discovery and genetic medicine.

Series B
$60M
10/09/2024
Article
R
ROME Therapeutics

Biotechnology • Autoimmune Diseases

Section 32 logo
Sanofi Ventures logo
Raycap logo
Mirae Asset Capital logo

ROME Therapeutics is a biotechnology company that develops breakthrough medicines for serious diseases, with a focus on an inhibitor of LINE-1 reverse transcriptase for autoimmune diseases, using their proprietary data science platform to identify active repeat elements and assess their roles in disease.

Series B
$72M
09/12/2023
Article